Drug class profile · refreshed daily from federal data

Antimalarial

6 molecules in this class, $61.4M combined CY2024 Part D spend across 145K claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 15 Oct 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Antimalarial class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 6tracked in Part D
CY24 Part D spend: $61.4Mcombined across class
Total Rx claims: 145K50K unique beneficiaries
Generic mfrs (active): 17across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Atovaquone

Brand: MEPRON · 136K Part D claims (CY24) · 45K beneficiaries · First FDA approval: 1995-02-28

7 generic mfrs 113 plans require PA

Low NADAC$0.719

→

Avg plan cost$0.763

Part D spend $60.4M 1× spread, current vs floor

Class share

98%

of class CY24 spend

View profile →

Chloroquine

5K Part D claims (CY24) · 3K beneficiaries · First FDA approval: 2011-07-01

4 generic mfrs 0 plans require PA

Low NADAC$2.54

→

Avg plan cost$5.28

Part D spend $591313 2× spread, current vs floor

Class share

of class CY24 spend

View profile →

Quinine

Brand: Quinine Sulfate · 4K Part D claims (CY24) · 2K beneficiaries · First FDA approval: 2012-09-28

4 generic mfrs 279 plans require PA

Low NADAC$0.698

→

Avg plan cost$0.698

Part D spend $418980 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Atovaquone Oral Suspension

Brand: ATOVAQUONE · — Part D claims (CY24) · First FDA approval: 2024-07-08

Brand-only (no generics)

Low NADAC$0.767

→

Avg plan cost$0.767

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Atovaquone and Proguanil

Brand: MALARONE · — Part D claims (CY24) · First FDA approval: 2000-07-26

2 generic mfrs 0 plans require PA

Low NADAC$0.927

→

Avg plan cost$1.42

Part D spend — 2× spread, current vs floor

Class share

of class CY24 spend

View profile →

Atovaquone and Proguanil Hydrochloride Pediatric

— Part D claims (CY24) · First FDA approval: 2015-04-08

Brand-only (no generics) 0 plans require PA

Low NADAC$0.927

→

Avg plan cost$0.927

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.